

Industry Expert Remi Corlin joins DOASENSE as International Markets Consultant

HEIDELBERG – 17 February 2020 – DOASENSE GmbH, an in vitro diagnostics company focused on the development and commercialization of innovative rapid tests, today announced that Remi Corlin has joined its team as International Markets Consultant. In this new role Mr. Corlin will coordinate the commercial launch of DOASENSE’s suite of products for point-of-care testing for direct oral anticoagulants (DOAC) in the international markets.

With many years of experience in building international market presence for companies like Haemonetics or Hemosonics, Remi Corlin is the latest addition to the DOASENSE team. DOASENSE offers a fast test that produces reliable results for both factor Xa and thrombin inhibitors within 10 minutes with one single DOAC Dipstick urine test. DOASENSE’s point-of-care test (POCT) answers the question whether a patient has ingested a DOAC. Thus, the necessary therapeutic decision can be taken as quickly as possible.

“I am delighted to join the DOASENSE team and to support the international roll-out of its first-in-class products,” said Remi Corlin. “With the DOAC Dipstick, DOASENSE has created a unique method for rapidly assessing at the critical point-of-care whether a patient has taken DOACs, thus successfully addressing a so far unmet medical need.”

About the DOASENSE Product Suite:

The CE-marked DOAC Dipstick is a qualitative all-in-one POCT for both direct factor Xa and thrombin inhibitor DOACs. The test is performed using a urine sample from the patient. The DOAC Dipstick provides results within 10 minutes where they are needed most: at the point-of-care. Specially developed accessories complete the first suite of CE-marked products for rapid point-of-care DOAC testing: Objective documentation of results can be achieved with the compact, automated DOASENSE Reader. And the DOASENSE Control Urines are specially designed reference substances to support quality assurance needs. The in vitro diagnostic products are for professional use only.

About DOASENSE:

DOASENSE is a medical technology company with operations in Heidelberg, Germany. DOASENSE’s exclusive, patent protected technology changes the way of testing for direct oral anticoagulants, serving an unmet clinical need.

The company is open to distributor inquiries for further broadening the international market presence of its products.

Contact:

DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany

info@doasense.de

www.doasense.de